Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Nocturnal hypoxemia portends cancer incidence

16 Jul 2020

Nocturnal hypoxemia is predictive of all-cancer incidence in patients suspected of having obstructive sleep apnoea (OSA), a study has found.

The study included a large multicentre cohort of 8,748 individuals (median age, 61 years; 64.5 percent male) who underwent a diagnostic sleep study. Of these, 1,161 (13.0 percent) had no OSA, 1,878 (21.5 percent) had mild OSA, 1,826 (21.0 percent) had moderate OSA, and 3,883 (44.5 percent) had severe OSA.

Patients with increasing OSA severity were of significantly higher age and body mass index and were more commonly male with medical history of diabetes, hypertension, cardiac disease, and alcohol consumption.

Over a median follow-up of 5.8 years, 718 participants (8.2 percent) developed cancer, with the most common sites being colorectal (n=129), lung (n=69), prostate (n=66), and breast (n=62). The incidence increased from 5.7 percent to 9.1 percent (p=0.0005) between the non-OSA group and the severe OSA group (incidence density rates, 10.0–16.6 per 1,000 person-years).

Kaplan-Meier survival analyses showed that cancer incidence was associated with increasing severity of OSA (p<0.0005) and nocturnal hypoxemia (p<0.0001 for both oxygen desaturation index and night-time with oxygen saturation <90 percent [T90]). The latter was associated with lung and breast malignancies specifically.

In adjusted Cox proportional-hazards models, only T90 conferred an increased risk of incident cancer (T90 ≥13 percent vs <0.01 percent: adjusted hazard ratio, 1.33, 95 percent confidence interval, 1.05–1.68; p=0.02). This association was more pronounced in older patients with obesity and no adequate OSA therapy.

Additional investigation is needed to evaluate whether OSA therapy might reduce the risk of cancer.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.